We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors (THBC001)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00440570
First Posted: February 27, 2007
Last Update Posted: June 29, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Barbault, Alexandre, M.S.
Information provided by:
Pasche, Boris, M.D.
  Purpose
In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment. We will conduct a feasibility study consisting of three daily ambulatory treatments until disease progression.

Condition Intervention Phase
Cancer Brain Tumor Device: Low levels of amplitude-modulated electromagnetic fields Device: Emitter of low levels of amplitude-modulated electromagnetic fields Early Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe

Resource links provided by NLM:


Further study details as provided by Pasche, Boris, M.D.:

Primary Outcome Measures:
  • Safety of daily administration of amplitude-modulated electromagnetic fields in patients with advanced cancer

Secondary Outcome Measures:
  • Complete blood count, comprehensive chemistry profile, tumor markers
  • Tumor assessment as per RECIST criteria

Estimated Enrollment: 2
Study Start Date: October 2004
Study Completion Date: December 2007
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a portable and programmable device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.

Methods: We will conducted a feasibility study consisting of three daily treatments. All patients with advanced solid tumors and measurable disease will be eligible, irrespective of prior treatments. Patients will be assessed with laboratory exams (complete blood count, comprehensive profile, tumor markers), imaging studies every other month for the first six months, every third month thereafter.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Advanced tumor that is either metastatic or inoperable

Exclusion Criteria:

  • Pregnancy,
  • Other simultaneous anticancer therapies,
  • ECOG performance status less than 3
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440570


Locations
Switzerland
Cabinet Médical Avenue de la gare 6
Lausanne, Vaud, Switzerland, 1012
Sponsors and Collaborators
Pasche, Boris, M.D.
Barbault, Alexandre, M.S.
Investigators
Principal Investigator: Boris C Pasche, MD, PhD Cabinet Médical Avenue de la gare 6
  More Information

Publications:
Responsible Party: Boris Pasche
ClinicalTrials.gov Identifier: NCT00440570     History of Changes
Other Study ID Numbers: 001
First Submitted: February 24, 2007
First Posted: February 27, 2007
Last Update Posted: June 29, 2011
Last Verified: June 2011

Keywords provided by Pasche, Boris, M.D.:
cancer
electromagnetic fields
treatment